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Circulating adipokines and C-reactive protein (CRP) have been linked to breast cancer risk in observational epidemiological
studies. The causal nature of these associations is unclear because of the susceptibility of conventional observational designs to
residual confounding, reverse causation and other forms of bias. Mendelian randomisation (MR) uses genetic variants as proxies
for risk factors to strengthen causal inference in observational settings. We performed a MR analysis to evaluate the causal
relevance of six previously reported circulating adipokines [adiponectin, hepatocyte growth factor (HGF), interleukin-6, leptin
receptor, plasminogen activator inhibitor-1 and resistin] and CRP in risk of overall and oestrogen receptor-stratified breast cancer
in up to 122,977 cases and 105,974 controls of European ancestry. Genetic instruments were constructed from single-nucleotide
polymorphisms robustly (p < 5 × 10−8) associated with risk factors in genome-wide association studies. Colocalisation was
performed as a sensitivity analysis to examine whether findings reflected shared causal variants or genomic confounding. In MR
analyses, there was evidence for an association of HGF with oestrogen receptor-negative cancer (odds ratio per standard deviation
increase: 1.17, 95% confidence interval: 1.01–1.35; p = 0.035) but little evidence for associations of other adipokines or CRP with
overall or oestrogen receptor-stratified breast cancer. Colocalisation analysis suggested that the association of HGF with
oestrogen receptor-negative breast cancer was unlikely to reflect a causal association. Collectively, these findings do not support
an important aetiological role of various adipokines or CRP in overall or oestrogen receptor-specific breast cancer risk.
Introduction
Elevated body mass index is an important modifiable risk factor
for breast cancer.1 With the discovery of adipose tissue as a
functioning endocrine organ, much attention has focused on a
putative role of adipokines – cytokines and hormones released
by adipose tissue – as molecular mediators linking excess adi-
posity to breast cancer.2–4 Two adipokines in particular – leptin
and adiponectin – have been strongly implicated in breast can-
cer aetiology. In vitro studies indicate that leptin may promote
human breast cancer cell proliferation and adiponectin may
exert antiproliferative effects5 and meta-analyses of observa-
tional studies support their opposing roles in breast cancer
risk.4,6,7 Likewise, several other adipokines including hepatocyte
growth factor (HGF), interleukin-6 (IL-6), plasminogen activa-
tor inhibitor-1 (PAI-1) and resistin have been linked to breast
cancer risk in observational studies, albeit less consistently.8–10
Prediagnostic C-reactive protein (CRP), a systemic marker of
inflammation that is synthesised in part by adipose tissue,11 has
also been associated with breast cancer risk in prospective
observational studies.12 Collectively, these observational find-
ings suggest that pharmacological targeting of adipokines or
CRP could be an effective strategy for breast cancer prevention
among overweight or obese women. However, the causal nature
of these risk factors in breast cancer risk, and thus their suitabil-
ity as intervention targets, is unclear. This is because of the
uncertain relevance of in vitro studies to humans, and the sus-
ceptibility of conventional observational analyses to residual
confounding and reverse causation, all of which undermines
causal inference.13,14
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Mendelian randomisation (MR) uses genetic variants as
instruments (‘proxies’) for risk factors (including those that
are potentially modifiable) to generate more reliable evidence
on the causal effects of these factors on disease outcomes and
so inform potential intervention strategies.15,16 The use of
genetic variants as instruments minimises confounding and
precludes reverse causation as germline genotype is largely
independent of lifestyle and environmental factors and is fixed
at conception. The statistical power and precision of MR anal-
ysis can be increased by employing a ‘two-sample MR’ frame-
work in which summary genetic association data from
independent samples representing genetic variant–exposure
and genetic variant–outcome associations are synthesised in
order to estimate causal effects.17
More formally, MR is a form of instrumental variable
(IV) analysis that can generate unbiased causal estimates of
effects of risk factors on disease and health-related outcomes if
the following conditions are met: (i) the instrument is robustly
associated with the exposure of interest, (ii) there is no con-
founding of the instrument–outcome relationship and (iii)
there is no pathway through which an instrument influences an
outcome except through the exposure (‘exclusion restriction
criterion’).
Given uncertainty surrounding the role of various previ-
ously reported adipokines and CRP in breast cancer aetiology,
we performed two-sample MR analyses to evaluate the causal
relevance of circulating adiponectin, HGF, IL-6, leptin recep-
tor, PAI-1, resistin and CRP in overall and oestrogen
receptor-stratified breast cancer risk.
Materials and Methods
Study population
Summary genome-wide association study (GWAS) statistics
were obtained from genome-wide meta-analyses on 122,977
breast cancer cases and 105,974 controls of European ances-
try.18 Summary statistics were also obtained from analyses on
69,501 oestrogen receptor-positive (ER+) and 21,468 oestrogen
receptor-negative (ER−) breast cancer cases (105,974 controls)
of European ancestry.18 Genotype data for a subset of the over-
all sample (61,282 cases and 45,494 controls) were obtained by
direct genotyping using an Illumina Custom Infinium array
(OncoArray) consisting of approximately 530,000 single-
nucleotide polymorphisms (SNPs) or by imputation with refer-
ence to the 10,000 Genomes Project Phase 3 reference panel.19
All SNPs with a call rate of < 95%, evidence of violation of
Hardy–Weinberg equilibrium (p < 1.0 × 10−7 in controls or
p < 1.0 × 10−12 in cases) and SNPs with concordance of <98%
among 5,280 duplicate sample pairs were removed. An addi-
tional 1,128 SNPs where the cluster plot was judged to be inad-
equate were removed. In imputation, the following SNPs were
additionally removed: those with a minor allele frequency of
<1%, a call rate of <98%, and those that could not be linked to
the 1,000 Genomes Project or differed significantly in frequency
from this panel. In total, 469,364 of the 533,631 SNPs that were
manufactured on the OncoArray were used in imputation.
Results for OncoArray analyses were combined with those from
the previous Illumina iSelect Collaborative Oncological Gene-
Environment Study (iCOGS) genotyping project (46,785 cases;
42,892 controls) along with 11 other breast cancer GWAS
(14,910 cases; 17,588 controls), using a fixed-effects meta-analy-
sis. The OncoArray, iCOGS and individual GWAS were
adjusted for principal components of ancestry and OncoArray
and iCOGS analyses were further adjusted for country and
study, respectively. All participating studies had the approval of
their appropriate ethics review board and all participants pro-
vided informed consent.
Instrument construction
Genetic instruments to proxy risk factors were constructed
either using a ‘monogenic’ approach (restricted to cis-acting
variants, i.e. located ≤1 MB of the transcription start site of the
protein-coding gene) or a ‘polygenic’ approach (combining cis-
and trans-acting variants, independent of genomic position),
depending on the number of genome-wide significant
(p < 5 × 10−8) variants available to proxy each respective risk
factor. When few SNPs are available as instruments, the restric-
tion of an instrument to cis-variants can help to minimise
horizontal pleiotropy (an instrument influencing an outcome
through one or more biological pathways independent to that
of the exposure), a violation of the exclusion restriction crite-
rion, as cis-variants are more likely to have direct effects on
protein levels than trans-variants (i.e. those >1 MB of the tran-
scription start site of the protein-coding gene).16 Genetic instru-
ments to proxy HGF, IL-6, leptin receptor and resistin were
constructed by obtaining cis-acting SNPs robustly associated
with these markers (p < 5 × 10−8) in GWAS of individuals of
European ancestry that were replicated in independent samples.
For risk factors with ≥3 independent (r2 < 0.01) cis- or trans-
SNPs available as proxies in GWAS of individuals of European
ancestry (adiponectin, CRP, PAI-1), these SNPs were combined
What’s new?
Adipokines and C-reactive protein have been linked to breast cancer risk in observational studies. But while these molecular
mediators potentially connect excess adiposity with breast cancer, whether the associations are causal in nature is uncertain.
Here, a Mendelian randomization approach was employed to estimate the causal effect of six circulating adipokines and C-
reactive protein on breast cancer risk. Overall, among 122,977 cases and 105,974 controls, analyses provided little evidence
supporting a causal role for these molecular markers in breast cancer etiology. The findings warrant investigation of other
mediators that could explain apparent links between adiposity and increased breast cancer risk.
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into multi-allelic instruments to increase the variance in the
risk factor explained by the instrument.20–22 As sensitivity ana-
lyses for adiponectin, CRP and PAI-1, effect estimates gener-
ated from multi-allelic instruments were compared to those
obtained from instruments consisting of weakly correlated
(r2 < 0.15) cis-variants to investigate horizontal pleiotropy in
primary multi-allelic models.23 Across GWAS used to instru-
ment various traits, sample sizes varied from 3,301 to 133,449
participants, mean ages of participants varied from 43.7 to
59.0 years, the proportion of females in the sample varied from
48.9 to 50.0%, and all participants were of European ancestry.
Study-level information on sample size, mean age and percent-
age of female participants are presented in Table 1. Estimates
of data set overlap across adipokine or CRP and breast cancer
analyses are presented in Supporting Information Table S1.
Complete summary genetic association data for all SNPs used
to instrument each trait is presented in Supporting Information
Table S2.
Statistical analysis
R2 and F-statistics were calculated to assess the strength of
instruments and to examine for weak instrument bias
(i.e. reduced statistical power to reject the null hypothesis when
an instrument explains a limited proportion of variance in an
exposure), using previously reported methods.26 For instru-
ments constructed using individual cis-variants (HGF, leptin
receptor, resistin and sensitivity analyses for PAI-1), effect esti-
mates were generated using the Wald ratio and standard errors
were approximated using the delta method. For instruments
constructed using ≥3 independent variants (adiponectin, CRP,
PAI-1), effect estimates were generated using inverse-variance
weighted (IVW) random-effects models to account for over-
dispersion in models.27 For instruments constructed using mul-
tiple weakly correlated cis-variants (IL-6 and sensitivity analyses
for adiponectin, CRP), effect estimates were generated using
IVW random-effects models with adjustment for correlations
between variants.28 If underdispersion was present in random-
effects models, the residual standard error was set to 1. For
instruments constructed using multiple independent variants
(adiponectin, CRP, PAI-1), MR-Egger (regression and intercept
parameter) and weighted median estimation were used to
evaluate for violations of the exclusion restriction criterion.27,29
MR-Egger regression can provide unbiased estimates of causal
effects even when all IVs in an instrument are invalid provided
that the instrument strength independent of direct effect
(InSIDE) assumption is met (i.e. that there is no association
between the strength of IV–exposure associations and the mag-
nitude of horizontal pleiotropy). The MR-Egger intercept can
provide a formal statistical test for directional pleiotropy
(i.e. where the net horizontal pleiotropic effect across an instru-
ment does not average to zero). The weighted median estimate
can provide unbiased estimates of causal effects when at least
50% of the information in an instrument derives from valid IVs.
This approach has two advantages over MR-Egger in that it
provides improved precision as compared to the latter and does
not rely on the InSIDE assumption. For adiponectin, CRP and
PAI-1 analyses, we also visually examined for evidence of poten-
tial outliers which may be indicative of horizontal pleiotropy by
generating scatter plots, forest plots and funnel plots. Leave-
one-out permutation analysis was also performed for these three
traits to examine whether any results were driven by an influen-
tial SNP within instruments.
As an additional sensitivity analysis, colocalisation was per-
formed to examine whether two traits showing evidence of an
association in MR analyses share the same causal variant at a
given locus. This is important to perform for analyses in
which an instrument is restricted to either a single variant or
a single gene region as findings may be more susceptible to
bias through genetic confounding (i.e., exposure and outcomes
are influenced by distinct causal variants that are in linkage
disequilibrium with each other). The coloc R package uses
approximate Bayes factor computation to generates posterior
probabilities that associations between two traits represent
each of the following configurations: (i) neither trait has a
genetic association in the region (H0), (ii) only the first trait
has a genetic association in the region (H1), (iii) only the sec-
ond trait has a genetic association in the region (H2), (iv) both
traits are associated but have different causal variants (H3)
and (v) both traits are associated and share a single causal var-
iant (H4).
30 An assumption of coloc is that there is at most
one causal variant per trait within the genomic region exam-
ined. Colocalisation analysis was performed for MR analyses
showing evidence of association (p < 0.05) by generating
Table 1. Characteristics of studies used to construct instrumental variables
Trait Author Sample size Mean age % Female
Adiponectin Dastani et al.20 30,708–38,276 NA NA
CRP Ligthart et al.22 204,402 NA NA
HGF Sun et al.24 3,301 43.7 48.9
IL-6 Swerdlow et al.25 133,449 59.0 49.0
Leptin receptor Sun et al.24 3,301 43.7 48.9
PAI-1 Huang et al.21 30,395 54.3 50.0
Resistin Sun et al.24 3,301 43.7 48.9
Abbreviations: CRP, C-reactive protein; HGF, hepatocyte growth factor; IL-6, interleukin-6; NA, not available in publication; PAI-1, plasminogen activator
inhibitor-1.
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windows 100 kb from the top SNP used to instrument the
exposure. As a convention, a posterior probability of ≥0.80
was used to indicate support for a configuration tested. To
evaluate assumptions of the coloc package (i.e. there is at most
one causal variant per trait) we also generated regional Man-
hattan plots for SNP-risk factor and SNP–breast cancer asso-
ciations to visually inspect whether there was evidence of
multiple independent causal variants within the region
examined.
To account for multiple testing across each breast cancer
endpoint (overall breast cancer risk, ER+ breast cancer risk,
ER− breast cancer risk), a Bonferroni correction was used
to establish a p-value threshold of <0.007 (false-positive
rate = 0.05/7 risk factors). All statistical analyses were per-
formed using R version 3.3.1.
Data availability
Summary genetic association data for all traits examined in
this study were obtained from previously published analyses
and can be made available upon reasonable request.18,20–25
Results
For each risk factor, the number of SNPs included in the instru-
ment and estimates of instrument strength (R2 and F-statistics)
are presented in Table 2. Across risk factors assessed, F-statistics
ranged from 40.1 to 3,872.7, suggesting that analyses were
unlikely to suffer from weak instrument bias.31 Conservative
estimates of sample overlap across GWAS data sets used ranged
from 0.0 to 7.3% (Supporting Information Table S1). Given
minimal sample overlap and likely absence of weak instrument
bias, the presence of overlap across some GWAS data sets is
unlikely to have introduced bias into these analyses.
In MR analyses, there was little evidence to suggest associa-
tions of any of the adipokines or CRP with overall breast can-
cer risk (Table 3). In ER status-stratified analyses, there was
evidence for an association of HGF with ER− breast cancer
risk [odds ratio (OR) per standard deviation (SD) increase:
1.17, 95% confidence interval (CI): 1.01–1.35; p = 0.035].
This finding did not reach statistical significance using a
Bonferroni-corrected threshold (p < 0.007). In sensitivity ana-
lyses, there was little evidence that this association colocalised
(posterior probability H4 = 0.055). Complete colocalisation
analysis results are presented in Supporting Information
Table S3. Regional Manhattan plots examining the association
of all SNPs 100 kb from the SNP used to instrument HGF
for their association with this adipokine (Fig. 1) and with ER
− breast cancer (Fig. 2) did not appear to support the pres-
ence of one or more independent causal variants for SNP-ER
− breast cancer analyses.
In all other ER-stratified analyses, there was little evidence of
association of other adipokines or CRP with breast cancer
outcomes.
Findings for adiponectin, PAI-1 and CRP in sensitivity
analyses using cis-SNP instruments for both overall and
oestrogen receptor-stratified breast cancer were consistent
with those from the primary analysis (Supporting Informa-
tion Table S4). Findings were also consistent for these three
risk factors when MR-Egger and weighted median estimation
was employed to test for evidence of exclusion restriction
Table 2. Number of SNPs included in instrument, estimate of the
proportion of variance in risk factor explained by the instrument (R2)
and F-statistic for each instrument, across all adipokines and CRP
Risk factor
Number of SNPs
in instrument R2 F-statistic
Adiponectin 8 0.016 60.8
CRP 45 0.035 119.4
HGF 1 0.012 40.1
IL-6 3 0.002 51.4
Leptin receptor 1 0.54 3,872.7
PAI-1 3 0.0064 65.5
Resistin 1 0.030 103.3
Abbreviations: CRP, C-reactive protein; HGF, hepatocyte growth factor; IL-6,
interleukin-6; PAI-1, plasminogen activator inhibitor-1; SNPs, single-
nucleotide polymorphisms.
R2 indicates proportion of variance in risk factor explained by genetic
instrument.
Table 3. Effect estimates per unit increase in adipokines or CRP on overall and oestrogen receptor-stratified breast cancer risk
Risk factor
Overall breast cancer ER+ breast cancer ER− breast cancer
OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
Adiponectin 1.06 (0.81–1.40) 0.66 0.98 (0.71–1.35) 0.91 1.19 (0.92–1.54) 0.18
CRP 1.03 (0.94–1.13) 0.48 1.04 (0.95–1.14) 0.40 1.05 (0.93–1.19) 0.41
HGF 1.01 (0.93–1.10) 0.77 1.01 (0.92–1.11) 0.86 1.17 (1.01–1.35) 0.035
IL-6 1.09 (0.96–1.25) 0.18 1.12 (0.96–1.31) 0.14 1.00 (0.79–1.27) 0.99
Leptin receptor 1.00 (0.99–1.01) 0.63 1.00 (0.99–1.01) 0.81 1.00 (0.98–1.02) 0.78
PAI-1 1.03 (0.80–1.33) 0.83 0.98 (0.78–1.24) 0.87 1.05 (0.65–1.68) 0.85
Resistin 0.98 (0.91–1.04) 0.48 0.98 (0.91–1.06) 0.61 0.99 (0.87–1.11) 0.81
Abbreviations: CI, confidence interval; CRP, C-reactive protein; ER+, oestrogen receptor positive; ER−, oestrogen receptor negative; HGF, hepatocyte
growth factor; IL-6, interleukin-6; OR, odds ratio; PAI-1, plasminogen activator inhibitor-1.
Effect estimates represent the effect of a one unit increase in: natural log-transformed adiponectin, CRP, IL-6 and PAI-1 and standardised HGF, leptin
receptor and resistin.
4 Mendelian randomisation analysis of circulating adipokines and C-reactive protein on breast cancer risk
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criterion violations (Supporting Information Table S5).
There were no clear violations of MR assumptions in forest,
funnel and scatter plots generated (Supporting Information
Figs. S1–S36).
Discussion
Our MR analyses in up to 122,977 breast cancer cases and
105,974 controls do not support an important aetiological role
of six adipokines or CRP in breast cancer risk. In analyses strati-
fied on oestrogen receptor status, there was some evidence for
an association of HGF with risk of oestrogen receptor-negative
breast cancer. However, this finding did not achieve statistical
significance based on a Bonferroni-corrected threshold to
account for multiple comparisons. Additionally, sensitivity anal-
ysis testing the probability that both traits share the same causal
variant found little evidence for colocalisation.
Our findings are not consistent with some previous con-
ventional observational analyses, notably those examining the
association of adiponectin and leptin with breast cancer.6–9,12
A meta-analysis of 15 cohort and case–control studies
reported a 34% risk reduction (95% CI: 13–50%) when com-
paring ‘highest’ to ‘lowest’ adiponectin levels, with moderate
heterogeneity across studies (I2 = 53%).6 Likewise, a meta-
analysis of 35 case–control studies reported a standardised
mean difference in serum leptin levels of 0.46 ng/ml (95%
CI: 0.31–0.60, I2 = 93.5%) when comparing breast cancer
cases to controls.7 However, four prospective studies examin-
ing the relationship between prediagnostic leptin and breast
cancer risk have shown conflicting results: two have
supported positive associations (upper vs. lower quartile: OR
1.94, 95% CI: 1.37–2.75; upper vs lower tertile: OR 1.98, 95%
CI: 1.20–3.29),32,33 whereas two found little evidence of asso-
ciation (upper vs lower quartile: OR 1.39, 95% CI: 0.93–2.09;
upper vs. lower tertile: OR 0.83, 95% CI: 0.51–1.37).3,34
Divergent findings across studies could be attributable to
residual confounding (due to unmeasured or imprecisely
measured confounders) or reverse causation in some conven-
tional observational analyses. For example, the ability to dis-
entangle highly correlated measured adipokine levels from
each other and from other metabolic perturbations associated
with the obese phenotype (e.g. insulin resistance, chronic
inflammation) may be limited when using conventional mul-
tivariable regression methods.35 Additionally, it is possible
that previously reported associations of inflammatory
markers like CRP with breast cancer could represent the
effect of early stage or latent breast cancer on subsequent
inflammation levels.36
Strengths of this analysis include the use of a MR approach
to appraise the relationship of adipokines and CRP with
breast cancer risk which should be less prone to confounding
than conventional observational analyses and cannot be
influenced by reverse causation. The use of a two-sample sum-
mary data MR framework afforded these analyses increased
statistical power and precision by exploiting summary genetic
data from several large genome-wide association studies. The
incorporation of colocalisation analysis permitted evaluation
of whether associations present were driven through genetic
confounding or shared common causal variants. Finally,
Figure 1. Regional Manhattan plot of associations of single-
nucleotide polymorphisms (SNPs) with circulating hepatocyte growth
factor (HGF) 100 kb from the SNP used to proxy HGF (rs5745695)
in the HGF region. [Color figure can be viewed at
wileyonlinelibrary.com]
Figure 2. Regional Manhattan plot of associations of single-
nucleotide polymorphisms (SNPs) with oestrogen receptor-negative
breast cancer 100 kb from the SNP used to proxy hepatocyte
growth factor (rs5745695) in the HGF region. [Color figure can be
viewed at wileyonlinelibrary.com]
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through restricting summary genetic association data to that
obtained in individuals of European descent and adjusted for
principal components of ancestry, these analyses reduced the
possibility of confounding through population substructures.
There are several limitations to these analyses. First, since
analyses were performed using summary genetic data in
aggregate, this precluded stratification according to meno-
pausal status. Around 85% of samples included within the
Breast Cancer Association Consortium (BCAC) data used
were classified as postmenopausal at diagnosis, suggesting that
findings were unlikely to be biased markedly by the presence
of premenopausal or perimenopausal participants.18 Second,
though attempts were made to circumvent potential violations
of MR assumptions in our analyses through the use of cis-
acting variants as primary instruments and in sensitivity ana-
lyses, we cannot rule out the possibility that false negative
findings may have arisen through horizontally pleiotropic
pathways biasing our findings toward the null. An assumption
of the colocalisation package employed is that there is at most
one causal variant per trait within the region examined. If
both traits have a genetic association in the region examined,
a low posterior probability generated for H4 (probability that
both traits share a single causal variant) could reflect the pres-
ence of multiple shared causal variants within that region.
However, posterior probabilities generated in this analysis
provided evidence that only HGF was likely to have an associ-
ation in the HGF region examined, suggesting that this
assumption was unlikely to be violated. Fourth, it is not
known whether circulating levels of adipokines represent a
good surrogate for tissue-specific levels in breast or adipose
tissue. Fifth, we were unable to examine potential nonlinear
associations of adipokines or CRP with breast cancer risk.
Beyond adipokines and inflammatory pathways, there are
several other molecular mechanisms through which excess adi-
posity may influence subsequent risk of breast cancer.37 For
example, recent MR evidence in the BCAC (N = 98, 842 cases;
83, 464 controls) has suggested that elevated fasting insulin, a
consequence of higher adiposity, increases breast cancer risk
(OR per SD increase = 1.71, 95% CI: 1.26–2.31).38 Along with
the recognised role of oestrogen levels in development of ER+
breast cancer, the hyperactivation of insulin-like growth factor
pathways and oxidative stress have also been implicated as
molecular mediators in breast carcinogenesis, both of which
may potentially influence disease through dysregulation of
mammalian target of rapamycin (mTOR) pathway signalling.37
Further examination of the putative role of these molecular
pathways in carcinogenesis could help to identify potential
pharmacological targets for the chemoprevention of breast
cancer in high-risk groups and, ultimately, help to reduce the
burden of breast cancer.
In conclusion, our MR analyses suggest that several
adipokines and CRP are unlikely to causally influence breast
cancer risk. Further exploration of potential molecular media-
tors linking adiposity to elevated breast cancer risk remains
warranted.
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